Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
ADVERTISEMENT FEATUREAdvertiser retains sole responsibility for the content of this article
Amunix unveils next-generation immunooncologic cancer therapy platform
A novel immunotherapy with extended serum half-life in a prodrug delivery format holds promise for overcoming the limitations of current BiTE therapies to treat a broad range of malignancies.